The two companies have announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic.
This new, non-exclusive collaboration reflects both companies′ commitment to making diabetes management easier by integrating key health technologies, they state.
“Millions of people living with diabetes work to control their sugar levels and track their insulin injections every day. To help ease the hassle of diabetes management, we are excited to be partnering with Medtronic, the largest medical device company in the world,” said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs, Novo Nordisk. “We now collaborate with all major CGM device producers, which means we can bring the benefits of smart insulin pens to even more people.”
Novo Nordisk expects to launch its durable smart insulin pens, NovoPen 6 and NovoPen Echo Plus, as well as its disposable, pre-filled injection solution starting in 2020. Once available, smart insulin pens will be compatible with both Android and iOS devices. The Guardian Connect system will be updated as well to integrate data from these Novo Nordisk smart pens.
Photo of Camilla Sylvest: Novo Nordisk